The Alpelisib Market size was valued at USD XX million in 2021 and is predicted to reach USD XX million by 2030 with a CAGR of XX% from 2022-2030. Alpelisib, commonly referred to Piqray, is a prescription medication that is used to treat cancer. It helps to block certain proteins including protein p110-alpha isoform that prevents cancer cells from growing. Alpelisib is also utilized in combination with fulvestrant medication to treat postmenopausal women and men who have HER2-negative hormone-receptor positive breast cancer that has spread widely or has a PIK3CA gene mutation. It is a protein kinase inhibitor that is a type of enzyme inhibitor that blocks the actions of protein kinases, which further helps to block certain cancer cells and also blocks the growth of new blood vessels to treat cancer. In addition, it is used in patients whose cancer got worse after treatment with hormone therapy. It is also used in the treatment of thalassemia and to treat patients undergoing leukemia by maintaining the required cell growth.
Market Dynamics and Trends
Increasing demand for alpelisib is due to rising cancer cases across the globe as alpelisib is used to treat certain cancer including breast cancer that has spread to nearby tissues or other parts of the body in women who have already gone through menopause. According to the American Cancer Society, unveil an estimated figure that there were 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2021. Also, the rapidly growing cases of breast cancer across the world drive the growth of the alpelisib market. For instance, according to the National Library of Medicine, in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Moreover, rising cases of menopausal women coupled with the lack of awareness regarding the treatment of menopause that leads to hot flashes, sleep disruption, and vaginal dryness is expected to further propel the growth of alpelisib market. For instance, in July 2021, according to State of Menopause Study, a survey was conducted with 1,039 women ages 40 to 65 across the US. It revealed that one-third (29%) of women never sought information about menopause before. Nearly half (45%) of women were unaware of the difference between perimenopause and menopause. And one-fifth (20%) of women experienced symptoms for a year or more before diagnosis. The highest (73%) of women were not treating their menopause.
However, high prices, unavailability of raw materials such as triethylamine along with the risk related to alpelisib that includes hyperglycemia (high blood sugar) are the factors restraining the growth of market during the forecast period. On the contrary, rising adoption of chemotherapy for cancer treatment along with the growing drug approvals for small-molecule injectables are expected to create ample growth opportunities for the market in the coming years.
Market Segmentations and Scope of the Study:
The alpelisib market is segmented on the basis of product type, application, distribution channel, and geography. On the basis of product type, the market is divided into piqray and vijoice. On the basis of application, the market is categorized into oncology, postmenopause, and others. On the basis of distribution channel, the market is segmented into hospital, pharmacies, retail pharmacies, drug stores, mail order pharmacies, and online. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising of North America, Europe, Asia-Pacific, and RoW.
North America holds the predominant share of alpelisib market at present and is expected to continue dominating the market during the forecast period. This is attributed to factors such as increasing usage of alpelisib-based molecular solutions for the treatment of and postmenopause among women along with the rising number of FDA approvals for alpelisib drugs in this region. For instance, in April 2022, Food and Drug Administration (FDA) approved Vijoice for adult and pediatric patients aged two years and over with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Also, the increasing cases of breast cancer among American women drive the demand for alpelisib market in this region. According to the American Cancer Society, an estimated figure of 287,850 new cases of invasive breast cancer diagnosed in women in 2022, which is increasing at the rate of 0.5% per year. According to the American Cancer Society, unveil an estimated figure that there were 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2021. On the other hand, Asia Pacific is expected to show a steady rise in the alpelisib market due to rising approvals for alpelisip drugs in this region. For instance, in July 2022, Philippine Food and Drug Administration (FDA) approved Novartis advanced breast cancer treatment ‘alpelisib’ in combination with fulvestrant for the treatment of postmenopausal with hormone receptor positive, human epidermal growth factor receptor-2 negative and others, advanced or metastatic breast cancer after disease progression following an endocrine-based regimen. Moreover, rising focus on the development of fulvestrant that is used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women, piqray and fulvestrant work together to shrink tumors in people with a PIK3CA mutation is expected to drive the alpelisib market growth in this region.
- The alpelisib market report provides the quantitative analysis of the current market and estimations through 2022-2030 that assists in identifying the prevailing market opportunities to capitalize on.
- The study comprises a deep dive analysis of the alpelisib market trend including the current and future trends for depicting the prevalent investment pockets in the market.
- The information related to key drivers, restraints and opportunities and their impact on the alpelisib market is provided in the report.
- The competitive analysis of the market players along with their market share in the alpelisib market
- The SWOT analysis and Porters Five Forces model is elaborated in the study.
- Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.
KEY MARKET SEGMENTS
- Alpelisib Market- By Product Type
- Alpelisib Market- By Application
- Alpelisib Market- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Alpelisib Market- By Geography
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Remaining countries
- North America